Roche, Ab­b­Vie forced to slam brakes on myelo­ma stud­ies of star drug Ven­clex­ta af­ter re­searchers flag high­er risk of death

Two heavy­weight phar­ma play­ers to­day said they’ve been forced to stop re­cruit­ing pa­tients for all on­go­ing stud­ies in­volv­ing Ven­clex­ta (vene­to­clax) for mul­ti­ple myelo­ma. Roche and Ab­b­Vie say the drug arm has been linked to a high­er rate of death than the con­trol group, prompt­ing the FDA to is­sue a par­tial hold or­der­ing them to sus­pend any new pa­tient re­cruit­ment for the blood can­cer tri­als un­til they can sort out what is hap­pen­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.